iOnctura
iOnctura is a clinical-stage precision oncology company developing first-in-class oral small molecule therapeutics (roginolisib, cambritaxestat, IOA-359) targeting neglected cancers including uveal melanoma, NSCLC, pancreatic cancer, CLL, and PTCL.
- Company typePrivate
- Founded2017
- HeadquartersGenève, Switzerland
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What iOnctura does
iOnctura is a clinical-stage precision oncology company founded in 2017, headquartered in Amsterdam (with Swiss subsidiary iOnctura SA in Geneva and US subsidiary iOnctura Inc. in Cambridge, Massachusetts), and led by co-founders Catherine Pickering (CEO) and Lars van der Veen (CSO). The company develops first-in-class oral small molecule therapeutics targeting three biological pathways relevant to the tumor-stroma-immune interface: PI3Kδ (via roginolisib/IOA-244, an allosteric modulator), autotaxin (via cambritaxestat/IOA-289), and TGF-β (via IOA-359). iOnctura focuses on neglected and hard-to-treat cancers with high unmet need, including uveal melanoma, non-small cell lung cancer, pancreatic cancer, myelofibrosis, chronic lymphocytic leukemia, and peripheral T-cell lymphoma, with over 180 patients treated with roginolisib across trials as of end-2025.
iOnctura's lead asset roginolisib is the first allosteric modulator of PI3Kδ, designed to avoid the immune-related toxicities associated with first-generation PI3K inhibitors while maintaining efficacy, with Phase II studies underway across multiple indications. Cambritaxestat is the only autotaxin inhibitor in clinical development for cancer, inhibiting both catalytic and chaperone activities of the enzyme, with its Phase Ib pancreatic cancer trial having met primary endpoints. IOA-359, a TGF-β pathway inhibitor, was in-licensed in 2023 with a development grant from Health Holland and KWF. The company has secured US FDA Orphan Drug Designation for both roginolisib (uveal melanoma) and cambritaxestat (pancreatic cancer), plus US FDA IND clearance and a UK MHRA ILAP Passport. iOnctura runs Phase I/II clinical trials globally, including at academic medical centers such as Dana-Farber Cancer Institute, University of Siena, and Humanitas Milan.
The company is pre-revenue with no commercialized products and does not generate product revenue; future revenue is expected to come from drug commercialization and licensing/royalties upon regulatory approval. iOnctura operates a sales-led enterprise go-to-market motion typical of clinical-stage biopharma, combining clinical trial partnerships with academic centers, medical science liaison engagement, business development activities with pharma partners (including a 2024 clinical collaboration with GSK for dostarlimab supply in NSCLC), and conference presence including the J.P. Morgan Healthcare Conference. The company has raised over €100M in private financing since 2017, including a €80-86M Series B in June 2024 led by Syncona with participation from EIC Fund, XGEN Venture, M Ventures, Inkef Capital, VI Partners, Schroders Capital, and 3B Future Health Fund. The leadership team and Board bring extensive prior biopharma experience from Merck KGaA, Eli Lilly, AbbVie, Novartis, Genmab, AstraZeneca, and other major oncology players.
iOnctura firmographics
Firmographics- Name
- iOnctura
- Legal name
- iOnctura SA
- Website
- https://ionctura.com
- Company type
- Private
- Founded year
- 2017
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- iOnctura is a clinical-stage precision oncology company developing first-in-class oral small molecule therapeutics (roginolisib, cambritaxestat, IOA-359) targeting neglected cancers including uveal melanoma, NSCLC, pancreatic cancer, CLL, and PTCL.
- Ownership category
- akta.pro rank
iOnctura industry classification
Industry- Product category
- Precision Oncology Therapeutics
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical and Medicine Manufacturing (3254)
- SIC
- Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833)
- akta.pro primary industry
- Rare Oncology & Hematologic Malignancy Therapies (HLAIAIAC)
Keywords
Where iOnctura is headquartered
LocationHeadquarters
- HQ city
- Genève
- HQ country
- Switzerland
- HQ region
- Europe
Offices3 records
Markets served
iOnctura business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales
Revenue model
- Biopharmaceutical Development: As a clinical-stage precision oncology company, iOnctura is developing small molecule therapeutics for cancer treatment. The company has not yet commercialized products and does not generate product revenue. Revenue will come from drug commercialization upon regulatory approval.
Go-to-market motion2 records
Distribution channels1 record
Marketing channels7 records
iOnctura product offering
Product offeringCore offering
iOnctura is a clinical-stage precision oncology company developing first-in-class oral small molecule therapeutics for neglected and hard-to-treat cancers. Its pipeline comprises three candidates — roginolisib (IOA-244, an allosteric PI3Kδ modulator), cambritaxestat (IOA-289, an autotaxin inhibitor), and IOA-359 (a TGF-β pathway inhibitor) — advancing through Phase I/II clinical trials across indications including uveal melanoma, NSCLC, pancreatic cancer, myelofibrosis, CLL, and PTCL. The company licenses and develops its drug candidates from Merck KGaA and Cancer Research UK and has not yet commercialized any product.
Product overview
iOnctura is a clinical-stage precision oncology company with a pipeline of first-in-class small molecules targeting neglected and hard-to-treat cancers. The company's portfolio consists of three main products: Roginolisib (IOA-244), the first allosteric modulator of PI3Kδ for treating uveal melanoma, NSCLC, CLL, myelofibrosis, and PTCL; Cambritaxestat (IOA-289), the only autotaxin inhibitor in clinical development for cancer, targeting pancreatic and liver malignancies; and IOA-359, a TGF-β pathway inhibitor for solid tumors. The company is developing these as oral small molecules designed to attack cancer from multiple angles, disrupt the tumor-stroma-immune interface, and overcome resistance mechanisms with low-toxicity profiles.
Differentiator
Problem solved
Functional benefit
Products and services
- Roginolisib (IOA-244) First-in-class oral small molecule and the first allosteric modulator of PI3Kδ with a unique chemical structure and binding mode. Allosteric modulation changes the 3D structure of the protein to affect its activity, providing exquisite selectivity over other PI3K isoforms and avoiding the immune-related toxicities of earlier-generation PI3K inhibitors. In clinical development for uveal melanoma, NSCLC, CLL, myelofibrosis, and PTCL.
- Cambritaxestat (IOA-289) First-in-class oral small molecule and the only autotaxin inhibitor currently in clinical development to treat cancer. Distinctively inhibits both the catalytic and the chaperone activities of the enzyme. Being developed for highly fibrotic tumors including pancreatic, liver, colorectal, ovarian, and breast cancers. Received US FDA Orphan Drug Designation for pancreatic cancer in 2024.
- IOA-359 Novel oral small molecule TGF-β pathway inhibitor being developed for solid tumors. Designed to override tumor survival pathways through data-driven precision oncology methods and novel combination treatments, addressing tumor aggressiveness, immune escape, and resistance to therapy.
Quantifiable outcome
- Doubled overall survival in uveal melanoma patients compared to historical controls (up to 4.5 years of treatment with roginolisib)
- +3 more outcomes
Companies that use iOnctura
Customer profileNamed customers4 records
Segments2 records
Ideal customer profiles3 records
iOnctura technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
iOnctura partnerships and signals
Strategic signalPartnerships
Five partnerships are on record, tiered major and core.
- Dana-Farber Cancer InstitutemajorDr. Jennifer Brown at Dana-Farber Cancer Institute received US Department of Defense funding to conduct a Phase I/II study of roginolisib in relapsed/refractory CLL, expanding US clinical trials.
- LYSARCmajoriOnctura is collaborating with LYSARC (The Lymphoma Academic Research Organisation) on the PlaTform Phase I/II platform trial investigating roginolisib in relapsed/refractory peripheral T-cell lymphoma (PTCL).
- GSKcoreGSK entered a clinical collaboration agreement to supply dostarlimab (anti-PD-1 monoclonal antibody) for use in the Phase II PULMO-01 study combining roginolisib with dostarlimab in NSCLC patients.
- Merck KGaAcoreiOnctura licensed cancer tumor research from Merck KGaA, including the technology that became roginolisib. CEO Catherine Pickering previously led oncology licensing at Merck KGaA.
- Cancer Research UKcoreiOnctura licensed cancer tumor research from Cancer Research UK, contributing to the development of the company's precision oncology pipeline.
Scale indicators8 records
Recent moves7 records
Expansion highlights7 records
iOnctura competitors and assessment
Company assessmentDirect peers
- Black Diamond Therapeutics: Clinical-stage precision oncology company developing small-molecule therapies against allosteric oncogenic mutations. Highly comparable given shared small-molecule precision oncology focus and the leadership overlap (Mark Velleca, iOnctura's Board Chair, is CEO of Black Diamond).
- Revolution Medicines: Late-stage clinical oncology company developing targeted small-molecule therapies for RAS-addicted cancers. Comparable in precision oncology small-molecule development with board-level overlap (Anthony Mancini, iOnctura board member, is CGO at Revolution Medicines).
- Cogent Biosciences: Clinical-stage precision oncology company developing targeted small molecules for hematologic malignancies and solid tumors. Comparable in clinical-stage precision oncology development targeting underserved cancer populations.
- Blueprint Medicines: Precision oncology company developing kinase-targeted small molecules. Highly comparable precision oncology business model, with a more advanced commercial stage providing reference valuation and pipeline benchmarks.
- Erasca: Clinical-stage precision oncology company focused on the RAS/MAPK pathway with PI3K inhibitors in development. Closely comparable given overlapping pathway focus and clinical-stage precision oncology model.
- Relay Therapeutics: Clinical-stage precision oncology company developing allosteric small-molecule inhibitors. Direct methodological comparability through allosteric modulation approach and similar clinical-stage development profile.
- Syndax Pharmaceuticals: Clinical-stage oncology company developing first-in-class therapies for unmet medical needs. Comparable clinical-stage oncology model with leadership overlap (Neil Gallagher, former President of R&D at Syndax, sits on iOnctura's board).
- Foghorn Therapeutics: Clinical-stage precision oncology company developing medicines targeting the chromatin regulatory system. Comparable clinical-stage precision oncology development profile with board overlap (Neil Gallagher sits on Foghorn's board).
Broad incumbents
- Incyte: Established commercial-stage biopharmaceutical company with a broad oncology portfolio including JAK inhibitors and PI3K inhibitors (duvelisib). Larger incumbent offering overlapping capabilities in oncology hematology and serves as a relevant benchmark for PI3K and precision oncology development.
- Genmab: Larger established oncology biotech with broad pipeline of antibody-based cancer therapies. Board-level overlap (Anthony Mancini, iOnctura board member, was COO at Genmab) and comparable oncology focus, though operating at substantially greater scale.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
iOnctura social profiles
Digital presenceiOnctura compliance and trust
Trust signalCompliance4 records
iOnctura financial estimates
Financial estimateRevenue estimate
Valuation estimate
iOnctura leadership team
Management profileNumber of profiles
Profiles13 records
iOnctura subsidiaries and ownership
Company hierarchySubsidiaries3 records
iOnctura funding detail
Funding detailFunding overview
Funding rounds9 records
Investors11 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
iOnctura M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about iOnctura
What does iOnctura do?
iOnctura is a clinical-stage precision oncology company developing first-in-class oral small molecule therapeutics for neglected and hard-to-treat cancers. Its pipeline comprises three candidates — roginolisib (IOA-244, an allosteric PI3Kδ modulator), cambritaxestat (IOA-289, an autotaxin inhibitor), and IOA-359 (a TGF-β pathway inhibitor) — advancing through Phase I/II clinical trials across indications including uveal melanoma, NSCLC, pancreatic cancer, myelofibrosis, CLL, and PTCL. The company licenses and develops its drug candidates from Merck KGaA and Cancer Research UK and has not yet commercialized any product.
Is iOnctura a public or private company?
iOnctura is a private company. It is classified as venture growth investor backed and is currently operating.
When was iOnctura founded?
iOnctura was founded in 2017. It employs 11 to 50 people.
Where is iOnctura based?
iOnctura is headquartered in Genève, Switzerland, in the Europe region.
How does iOnctura make money?
One revenue line is on record: biopharmaceutical Development.
Who are iOnctura's main competitors?
Direct peers on record are Black Diamond Therapeutics, Revolution Medicines, Cogent Biosciences, Blueprint Medicines, Erasca, Relay Therapeutics, Syndax Pharmaceuticals and Foghorn Therapeutics. Broad incumbents are Incyte and Genmab.
Does iOnctura have an API?
No public API is recorded for iOnctura.
What industry is iOnctura in?
iOnctura's product category is Precision Oncology Therapeutics. Its primary akta.pro industry code is HLAIAIAC, Rare Oncology & Hematologic Malignancy Therapies. Its NAICS code is 541714 and its SIC code is 2834.